

Rituximab after Autologous Stem-Cell Transplantation

New England Journal of Medicine

377, 1250-1260

DOI: [10.1056/nejmoa1701769](https://doi.org/10.1056/nejmoa1701769)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Extended EFS with rituximab. Nature Reviews Clinical Oncology, 2017, 14, 714-714.	12.5	1
2	The role of B cell antigen receptors in mantle cell lymphoma. Journal of Hematology and Oncology, 2017, 10, 164.	6.9	17
3	Does maintenance therapy have a role in mantle cell lymphoma treatment?. Expert Review of Hematology, 2018, 11, 285-292.	1.0	1
4	Improving on R-ICE in relapsed DLBCL. Blood, 2018, 131, 1767-1768.	0.6	1
5	Rituximab maintenance versus observation following abbreviated induction with chemoimmunotherapy in elderly patients with previously untreated chronic lymphocytic leukaemia (CLL 2007 SA): an open-label, randomised phase 3 study. Lancet Haematology, the, 2018, 5, e82-e94.	2.2	23
7	Lacrimal Gland Tumors. International Ophthalmology Clinics, 2018, 58, 197-235.	0.3	3
8	Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the <sc>UK</sc>'s Haematological Malignancy Research Network (<sc>HMRN</sc>). British Journal of Haematology, 2018, 181, 215-228.	1.2	36
9	The possible role of maintenance treatment for primary central nervous system lymphoma. Blood Reviews, 2018, 32, 378-386.	2.8	20
10	What is the optimal initial management of the younger mantle cell lymphoma patient?. Best Practice and Research in Clinical Haematology, 2018, 31, 90-98.	0.7	2
11	Indolent B-cell lymphomas. , 2018, , .		0
14	Maintenance Treatment for Patients With Mantle Cell Lymphoma. HemaSphere, 2018, 2, e136.	1.2	9
15	Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. American Journal of Hematology, 2018, 94, E50-E53.	2.0	8
16	Bulky primary tibia mantle cell lymphoma achieved complete remission with CHOP and DHAP plus rituximab: A case report. Oncology Letters, 2018, 16, 6116-6120.	0.8	1
17	Bortezomib-based chemotherapy in mantle cell lymphoma. Lancet Oncology, The, 2018, 19, 1419-1421.	5.1	6
18	Optimal frontline management of mantle cell lymphoma: can we agree?. Expert Review of Hematology, 2018, 11, 911-914.	1.0	1
19	Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood, 2018, 132, 2016-2025.	0.6	93
20	Current overview and treatment of mantle cell lymphoma. F1000Research, 2018, 7, 1136.	0.8	32
21	What is the Optimal Initial Management of the Younger Mantle Cell Lymphoma Patient?. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S99-S100.	0.2	0

#	ARTICLE	IF	CITATIONS
22	Guideline for the management of mantle cell lymphoma. British Journal of Haematology, 2018, 182, 46-62.	1.2	38
23	Râ€Highâ€<scp>CHOP</scp>/<scp>CHASER</scp>/<scp>LEED</scp> with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer Science, 2018, 109, 2830-2840.	1.7	14
24	Rituximab maintenance therapy for mantle cell lymphoma: A systematic review and metaâ€analysis. American Journal of Hematology, 2018, 93, 1220-1226.	2.0	9
25	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematology and Oncology, 2018, 11, 87.	6.9	12
26	Past, Present, and Future of Rituximabâ€”The Worldâ€™s First Oncology Monoclonal Antibody Therapy. Frontiers in Oncology, 2018, 8, 163.	1.3	238
27	Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma. Current Treatment Options in Oncology, 2018, 19, 45.	1.3	5
28	Evolving treatment strategies in mantle cell lymphoma. Best Practice and Research in Clinical Haematology, 2018, 31, 270-278.	0.7	6
29	Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma. Current Oncology Reports, 2018, 20, 79.	1.8	11
30	Update on mantle cell lymphoma. Blood, 2018, 132, 1647-1656.	0.6	144
32	Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. Bone Marrow Transplantation, 2019, 54, 17-25.	1.3	4
33	The use of ibrutinib before and after allogeneic stem cell transplantation. Expert Opinion on Orphan Drugs, 2019, 7, 171-180.	0.5	1
34	Clinical management of mantle cell lymphoma in the elderly. Expert Opinion on Pharmacotherapy, 2019, 20, 1893-1905.	0.9	3
35	Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies. Cancers, 2019, 11, 1071.	1.7	32
36	Optimal management of mantle cell lymphoma in the primary setting. Expert Review of Hematology, 2019, 12, 715-721.	1.0	0
38	<p>Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy</p>. OncoTargets and Therapy, 2019, Volume 12, 8003-8014.	1.0	5
39	Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma. International Journal of Molecular Sciences, 2019, 20, 4417.	1.8	23
41	Mantle Cell Lymphoma: Which Patients Should We Transplant?. Current Hematologic Malignancy Reports, 2019, 14, 239-246.	1.2	6
42	Phase 1â€2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed Bâ€cell nonâ€Hodgkin lymphoma and previously untreated mantle cell lymphoma. British Journal of Haematology, 2019, 186, 845-854.	1.2	18

#	ARTICLE	IF	CITATIONS
43	The modern approach to mantle cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 66-69.	0.8	22
44	Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. <i>Blood Cancer Journal</i> , 2019, 9, 50.	2.8	75
45	Therapeutic antibodies for mantle cell lymphoma: A brand-new era ahead. <i>Heliyon</i> , 2019, 5, e01297.	1.4	5
46	A multicenter retrospective comparison of induction chemoimmunotherapy regimens on outcomes in transplant-eligible patients with previously untreated mantle cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 253-260.	0.8	5
47	When to use stem cell transplant in mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2019, 12, 207-210.	1.0	4
48	Frontline management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma. <i>Internal Medicine Journal</i> , 2019, 49, 1070-1080.	0.5	8
50	Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2255-2263.	0.6	0
51	Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. <i>American Journal of Hematology</i> , 2019, 94, 710-725.	2.0	151
52	Consolidation with ⁹⁰ Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up. <i>Leukemia and Lymphoma</i> , 2019, 60, 2689-2696.	0.6	6
53	Turning Point in the Treatment of Mantle Cell Lymphoma. <i>Yonago Acta Medica</i> , 2019, 62, 001-007.	0.3	1
54	Frontline treatment of diffuse large B-cell lymphoma: Beyond R-CHOP. <i>Hematological Oncology</i> , 2019, 37, 333-344.	0.8	38
55	Mantle cell lymphoma and its management: where are we now?. <i>Experimental Hematology and Oncology</i> , 2019, 8, 2.	2.0	28
56	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
57	The Emerging Role of Liquid Biopsies in Lymphoproliferative Disorders. <i>Current Hematologic Malignancy Reports</i> , 2019, 14, 11-21.	1.2	4
58	Front-line therapy in elderly patients with mantle cell lymphoma. <i>Annals of Lymphoma</i> , 0, 3, 8-8.	4.5	2
59	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	2.5	18
60	Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation. <i>Current Opinion in Oncology</i> , 2019, 31, 374-379.	1.1	4
61	Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry. <i>Leukemia and Lymphoma</i> , 2019, 60, 748-755.	0.6	7

#	ARTICLE	IF	CITATIONS
62	A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. <i>Haematologica</i> , 2019, 104, 138-146.	1.7	37
63	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 999-1005.	1.2	29
64	Dynamic molecular monitoring reveals that SWI5H SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. <i>Nature Medicine</i> , 2019, 25, 119-129.	15.2	147
65	Acalabrutinib for adults with mantle cell lymphoma. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 179-187.	1.3	9
66	Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 943-960.	1.3	13
67	Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, <i>in-vitro</i> proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model. <i>Oncolmmunology</i> , 2019, 8, e1512455.	2.1	17
68	Etoposide phosphate for pediatric orthopedic malignancies after intravenous etoposide hypersensitivity. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 228-231.	0.5	6
69	<i>KMT2D</i> mutations and <i>TP53</i> disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , 2020, 105, 1604-1612.	1.7	96
70	Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project. <i>Haematologica</i> , 2020, 105, e33-e36.	1.7	31
71	JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-4. Mantle cell lymphoma (MCL). <i>International Journal of Hematology</i> , 2020, 111, 5-15.	0.7	4
72	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 248-256.	0.8	73
73	Mantle cell lymphoma: a rare cause for a swollen palate. <i>BMJ Case Reports</i> , 2020, 13, e238332.	0.2	2
74	Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 861-870.	0.9	2
75	Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. <i>Blood Advances</i> , 2020, 4, 4849-4859.	2.5	14
76	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 957-970.	0.9	6
77	Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group. <i>Lancet Haematology</i> , 2020, 7, e798-e807.	2.2	12
78	Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 983-996.	0.9	0
79	Recent advances in the first-line treatment of mantle cell lymphoma. <i>Annals of Lymphoma</i> , 0, 4, 2-2.	4.5	4

#	ARTICLE	IF	CITATIONS
80	Improving outcomes after autologous transplantation in relapsed/refractory Hodgkin lymphoma: a European expert perspective. <i>BMC Cancer</i> , 2020, 20, 1088.	1.1	12
81	Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 971-982.	0.9	1
83	Advances in Classification and Treatment of Non-Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 348-356.	1.0	2
84	Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 3486-3494.	2.5	23
85	Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 6573-6581.	1.0	10
86	Chemotherapy combinations for B-cell lymphoma and chemo-free approach in elderly patients: an update on best practice. <i>Expert Review of Hematology</i> , 2020, 13, 851-869.	1.0	2
87	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	26
88	Management of Relapsed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S98-S100.	0.2	0
89	Mantle cell lymphoma: insights into therapeutic targets at the preclinical level. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 1029-1045.	1.5	4
90	Subgroup analysis in haematologic malignancies phase III clinical trials: A systematic review. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2635-2644.	1.1	6
91	Management of Older Adults with Mantle Cell Lymphoma. <i>Drugs and Aging</i> , 2020, 37, 469-481.	1.3	4
92	Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the <sc>LYSA</sc> group. <i>Hematological Oncology</i> , 2020, 38, 446-455.	0.8	5
93	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020, 4, 858-867.	2.5	40
94	Treatment of mantle cell lymphoma in Asia: a consensus paper from the Asian Lymphoma Study Group. <i>Journal of Hematology and Oncology</i> , 2020, 13, 21.	6.9	17
95	Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. <i>British Journal of Haematology</i> , 2020, 190, 385-393.	1.2	11
96	Drug Resistance in Non-Hodgkin Lymphomas. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2081.	1.8	37
97	Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: <sc>CALGB</sc>/Alliance 50403. <i>American Journal of Hematology</i> , 2020, 95, 583-593.	2.0	18
98	Systematic literature review of the global burden of illness of mantle cell lymphoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 843-852.	0.9	3

#	ARTICLE	IF	CITATIONS
99	Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA. <i>Annals of Hematology</i> , 2020, 99, 1771-1778.	0.8	8
100	Mantle cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103038.	2.0	21
101	Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. <i>Annals of Pharmacotherapy</i> , 2020, 54, 879-898.	0.9	4
102	Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry. <i>Annals of Hematology</i> , 2020, 99, 1073-1079.	0.8	5
103	Mantle cell lymphoma "where precision medicine based on response-adapted treatment strategies could show its full worth. <i>British Journal of Haematology</i> , 2020, 189, 600-602.	1.2	0
104	Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. <i>Bone Marrow Transplantation</i> , 2020, 55, 1076-1084.	1.3	20
105	Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 904.	1.8	13
106	An update on options of therapy for aggressive mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2036-2049.	0.6	0
107	Maintenance Strategies After Hematopoietic Cell Transplantation. <i>Pharmacotherapy</i> , 2020, 40, 727-740.	1.2	2
108	Oncology Practice During the COVID-19 Pandemic. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 2005.	3.8	221
109	A phase II trial evaluating the efficacy of high-dose Radioiodinated Tositumomab (Anti-CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high-risk relapsed or refractory non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2020, 95, 775-783.	2.0	7
110	Novel agents for mantle cell lymphoma: molecular rational and clinical data. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 555-566.	1.9	7
111	How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. <i>Hematology, Transfusion and Cell Therapy</i> , 2020, 42, 103-110.	0.1	33
112	Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience. <i>Blood Research</i> , 2020, 55, 57-61.	0.5	1
113	Intraocular involvement of Mantle cell lymphoma: A case report and literature review. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2021, 14, 147-152.	0.6	3
114	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. <i>Blood</i> , 2021, 137, 877-887.	0.6	68
115	Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. <i>British Journal of Haematology</i> , 2021, 193, 15-25.	1.2	20
116	Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. <i>British Journal of Haematology</i> , 2021, 192, 737-746.	1.2	13

#	ARTICLE	IF	CITATIONS
117	High-Risk Mantle Cell Lymphoma in the Era of Novel Agents. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 8-18.	1.2	5
118	Minimal Residual Disease and Survival Outcomes in Patients with Mantle Cell Lymphoma: a systematic review and meta-analysis. <i>Journal of Cancer</i> , 2021, 12, 553-561.	1.2	7
119	Relapse After Hematopoietic Cell Transplantation. , 2021, , 711-721.		0
120	Autologous Bone Marrow Transplant. <i>Organ and Tissue Transplantation</i> , 2021, , 297-313.	0.0	0
121	Hodgkin Lymphoma and Non-Hodgkin Lymphoma. , 2021, , 271-281.		0
122	The M factor: maintenance in mantle cell lymphoma. <i>Lancet Haematology</i> ,the, 2021, 8, e3-e4.	2.2	0
123	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> ,the, 2021, 8, e34-e44.	2.2	29
124	Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?. <i>Current Hematologic Malignancy Reports</i> , 2021, 16, 82-88.	1.2	1
125	Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: A systematic literature review. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 158, 103212.	2.0	8
126	Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?. <i>Journal of Clinical Oncology</i> , 2021, 39, 487-498.	0.8	27
127	Towards ecosystem integration for a better understanding of aggressiveness of B-cell lymphomas. <i>British Journal of Haematology</i> , 2021, 193, 447-448.	1.2	0
129	Mantle cell lymphoma " advances in molecular biology, prognostication and treatment approaches. <i>British Journal of Haematology</i> , 2021, 195, 162-173.	1.2	31
130	Unmarried or less-educated patients with mantle cell lymphoma are less likely to undergo a transplant, leading to lower survival. <i>Blood Advances</i> , 2021, 5, 1638-1647.	2.5	8
131	Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions. <i>Journal of Clinical Medicine</i> , 2021, 10, 1207.	1.0	11
132	How should we use ibrutinib in patients with mantle cell lymphoma?. <i>British Journal of Haematology</i> , 2021, 193, 445-446.	1.2	0
133	Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells. <i>Drugs</i> , 2021, 81, 669-684.	4.9	2
134	Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 1700-1709.	1.3	6
135	MACLO-VAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma " Long term follow up results. <i>American Journal of Hematology</i> , 2021, 96, 680-689.	2.0	1

#	ARTICLE	IF	CITATIONS
136	Allogeneic stem cell transplantation for mantle cell lymphoma—update of the prospective trials of the East German Study Group Hematology/Oncology (OSHO#60 and #74). <i>Annals of Hematology</i> , 2021, 100, 1569-1577.	0.8	6
137	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. <i>Future Oncology</i> , 2021, 17, 1269-1283.	1.1	20
138	Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. <i>British Journal of Haematology</i> , 2021, 194, 365-377.	1.2	13
139	B Cell Lymphomas of the GI Tract. <i>Current Gastroenterology Reports</i> , 2021, 23, 9.	1.1	5
140	Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population. <i>BMC Cancer</i> , 2021, 21, 566.	1.1	1
141	Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome After High-Dose Chemotherapy. <i>Cancers</i> , 2021, 13, 2558.	1.7	2
142	Cellular Therapies for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 363-370.	0.6	6
143	Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions. <i>International Journal of Hematologic Oncology</i> , 2021, 10, IJH33.	0.7	11
144	Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress. <i>Journal of Hematology and Oncology</i> , 2021, 14, 88.	6.9	41
145	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
146	Mantle cell lymphoma—Advances in molecular biology, prognostication and treatment approaches. <i>Hematological Oncology</i> , 2021, 39, 31-38.	0.8	8
147	COVID-19 vaccination in patients on rituximab: a survey of lymphoma physicians at NCI designated cancer centers. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-4.	0.6	3
148	The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells. <i>HemaSphere</i> , 2021, 5, e620.	1.2	5
149	Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term. <i>Bone Marrow Transplantation</i> , 2021, 56, 2606-2609.	1.3	3
150	Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 911.e1-911.e7.	0.6	6
151	Efficacy of chemotherapy protocols for hematological malignancies: H-CVAD versus GELA/BURKIMAB/PETHEMA LAL. <i>Experimental Hematology</i> , 2021, 101-102, 49-57.	0.2	2
152	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
153	Multi-center analysis of practice patterns and outcomes of younger and older patients with mantle cell lymphoma in the rituximab era. <i>American Journal of Hematology</i> , 2021, 96, 1374-1384.	2.0	11

#	ARTICLE	IF	CITATIONS
154	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	0.6	7
155	Deep-Learning Assessed Muscular Hypodensity Independently Predicts Mortality in DLBCL Patients Younger Than 60 Years. <i>Cancers</i> , 2021, 13, 4503.	1.7	7
156	The role of autologous haematopoietic stem-cell transplantation in mantle cell lymphoma. <i>Lancet Haematology</i> , 2021, 8, e617-e619.	2.2	3
157	Prognostic Role of Serum Albumin Level in Patients with Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Annals of Transplantation</i> , 2021, 26, e933365.	0.5	1
158	Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e648-e657.	2.2	27
159	Exploiting gene mutations and biomarkers to guide treatment recommendations in mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2021, 14, 1-17.	1.0	2
160	The impact of socioeconomic disparities on the use of upfront autologous stem cell transplantation for mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 335-343.	0.6	5
161	History and Development of Autologous Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Clinical Hematology International</i> , 2021, 3, 83.	0.7	5
162	Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version). <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 289-301.	0.7	34
163	Mantle Cell Lymphoma. <i>Hematologic Malignancies</i> , 2021, , 163-178.	0.2	0
164	Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110188.	1.1	0
165	Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma in the Era of New Drugs and CAR-T Cell Therapy. <i>Cancers</i> , 2021, 13, 291.	1.7	17
166	Mantle Cell Lymphoma. , 2020, , 69-82.		1
167	Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3. <i>HemaSphere</i> , 2021, 5, e510.	1.2	18
168	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11
169	Molecular profiling and management of mantle cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , 2019, 2019, 30-40.	0.9	6
170	Intermediate Results of Prospective Observational Study: The 2-year Experience of Ibrutinib Therapy in Relapsed/Refractory Mantle Cell Lymphoma in Clinical Practice. <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2019, 12, 65-72.	0.1	1
172	Dose Finding Study of Ibrutinib and Venetoclax in Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood Advances</i> , 2021, , .	2.5	5

#	ARTICLE	IF	CITATIONS
173	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. <i>Blood Advances</i> , 2022, 6, 1350-1360.	2.5	9
174	Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy. <i>Nature Communications</i> , 2021, 12, 6071.	5.8	44
175	Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2021, 62, 3474-3483.	0.6	7
176	Hematopoietic Stem Cell Transplantation. , 2017, , .		0
177	Old Dog, New Tricks: Targeting CD20 in B Cell Non-Hodgkin Lymphomas. , 2018, 15, .		0
178	An Attempt to Quantitate "Value" In Medical Oncologic Therapy. <i>Cureus</i> , 2018, 10, e2810.	0.2	1
179	Mantle Cell Lymphoma. , 2019, , 643-646.		0
180	Prevention and Treatment of Relapse by Drugs. , 2019, , 437-442.		1
181	Can We Use MRD Status to Personalize Therapy in Mantle Cell Lymphoma?. , 2019, 16, .		0
182	Mantle cell lymphoma: Saudi Lymphoma Group's clinical practice guidelines for diagnosis, management and follow-up. <i>Saudi Journal of Medicine and Medical Sciences</i> , 2019, 7, 226.	0.3	1
183	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2020, , 463-512.		0
184	The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 1035-1038.	1.2	10
185	Hematopoietic Progenitor Cell Transplantation in Children, Adolescents, and Young Adults With Relapsed Mature B-Cell NHL. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1135-1142.	2.3	0
186	Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENABERIT) experience. <i>Hematological Oncology</i> , 2022, 40, 23-31.	0.8	1
187	Mantle Cell Lymphoma: History, Current Principles of Diagnosis, and Treatment (Literature Review). <i>Klinicheskaya Onkogematologiya/Clinical Oncohematology</i> , 2020, 13, 366-381.	0.1	0
188	First-Line Therapy, Autologous Stem-Cell Transplantation, and Post-Transplantation Maintenance in the Management of Newly Diagnosed Mantle Cell Lymphoma. <i>Current Oncology</i> , 2020, 27, 632-644.	0.9	1
189	Mantle Cell Lymphoma: Therapeutics and Management. <i>Molecular and Translational Medicine</i> , 2020, , 163-177.	0.4	0
190	Autologous Bone Marrow Transplant. <i>Organ and Tissue Transplantation</i> , 2020, , 1-17.	0.0	0

#	ARTICLE	IF	CITATIONS
191	Therapeutic options for relapsed/refractory mantle cell lymphoma. <i>Blood</i> , 2022, 139, 666-677.	0.6	27
192	Consenso del Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL) para el manejo del Linfoma en estado de Pandemia SARS CoV-2 / COVID 19. <i>Revista Colombiana De Cancerología</i> , 0, 24, .	0.0	2
194	Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute. <i>Blood Advances</i> , 2020, 4, 3205-3208.	2.5	3
195	Non-Hodgkin-Lymphome. , 2022, , 195-203.		0
196	How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen. <i>Current Oncology</i> , 2021, 28, 4611-4633.	0.9	4
197	NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1218-1230.	2.3	98
198	Mantle cell lymphoma: A clinical review of the changing treatment paradigms with the advent of novel therapies, and an insight into Indian data. <i>Cancer Reports</i> , 2021, , e1590.	0.6	3
199	Outcome of patients with mantle cell lymphoma after autologous stem cell transplantation in the preâ€CAR Tâ€cell era. <i>Hematological Oncology</i> , 2022, 40, 292-296.	0.8	6
200	Current Knowledge in Genetics, Molecular Diagnostic Tools, and Treatments for Mantle Cell Lymphomas. <i>Frontiers in Oncology</i> , 2021, 11, 739441.	1.3	3
201	Successful implementation of outpatient Râ€™%â€™DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience. <i>Leukemia and Lymphoma</i> , 2022, 63, 876-884.	0.6	1
202	New indications and platforms for CARâ€™T therapy in lymphomas beyond DLBCL. <i>EJHaem</i> , 2022, 3, 11-23.	0.4	2
203	Sequencing of Novel Therapies for Mantle Cell Lymphoma. <i>Current Treatment Options in Oncology</i> , 2021, 22, 118.	1.3	3
204	Dissociated humoral and cellular immune responses after a three-dose schema of BNT162b2 vaccine in patients receiving anti-CD20 monoclonal antibody maintenance treatment for B-cell lymphomas. <i>Haematologica</i> , 2022, 107, 755-758.	1.7	6
205	Managing Relapsed Mantle Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	2
206	Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib â€™ Case Report. <i>Journal of Education, Health and Sport</i> , 2020, 10, 299-307.	0.0	0
207	Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study. <i>Frontiers in Oncology</i> , 2021, 11, 770988.	1.3	3
208	A narrative review of consolidation strategies for young and fit patients with newly-diagnosed primary central nervous system lymphoma. <i>Expert Review of Hematology</i> , 2021, , 1-11.	1.0	2
209	Hematopoietic cell transplantation for mantle cell lymphoma. <i>International Journal of Hematology</i> , 2022, 115, 301.	0.7	0

#	ARTICLE	IF	CITATIONS
210	Frontline chemotherapy-free induction for mantle cell lymphoma. <i>Lancet Oncology</i> , The, 2022, , .	5.1	0
211	Ibrutinib+rituximab followed by R-HCVAD as frontline treatment for young patients (>65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 406-415.	5.1	22
212	Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study. <i>Bone Marrow Transplantation</i> , 2022, 57, 627-632.	1.3	4
213	Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 2667-2680.	2.5	17
215	Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	7
216	Mantle cell lymphoma management trends and novel agents: where are we going?. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	1.1	8
217	Humoral immune-depression following autologous stem cell transplantation is a marker of prolonged response duration in patients with mantle cell lymphoma. <i>Haematologica</i> , 2022, , .	1.7	0
218	Ofatumumab plus HyperCVAD/HD+MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study. <i>Cancer</i> , 2022, 128, 1595-1604.	2.0	2
219	A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2023, 64, 722-724.	0.6	1
220	Relapsed/Refractory Mantle Cell Lymphoma: Beyond BTK Inhibitors. <i>Journal of Personalized Medicine</i> , 2022, 12, 376.	1.1	9
221	Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. <i>American Journal of Hematology</i> , 2022, 97, 638-656.	2.0	48
222	Stem cell transplant for mantle cell lymphoma in Taiwan. <i>Scientific Reports</i> , 2022, 12, 5662.	1.6	3
223	Survival in mantle cell lymphoma after frontline treatment with R-bendamustine, R-CHOP and the Nordic MCL2 regimen — a real world study on patients diagnosed in Sweden 2007-2017. <i>Haematologica</i> , 2022, 107, 740-743.	1.7	9
224	Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 5285-5294.	2.5	7
226	Current and emerging monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies in treatment of lymphoma. <i>Leukemia Research Reports</i> , 2022, 17, 100319.	0.2	0
227	Efficacy and safety of autologous hematopoietic stem cell transplantation in the treatment of malignant lymphoma after chemotherapy: a systematic review and meta-analysis. <i>Translational Cancer Research</i> , 2022, 11, 888-896.	0.4	1
228	New Directions for Mantle Cell Lymphoma in 2022. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 614-628.	1.8	14
229	Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma. <i>Blood Advances</i> , 2022, 6, 4122-4131.	2.5	8

#	ARTICLE	IF	CITATIONS
230	Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. <i>Cancers</i> , 2022, 14, 2532.	1.7	1
231	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	1.2	1
232	Mantle Cell Lymphoma: the Role of Risk-Adapted Therapy and Treatment of Relapsed Disease. <i>Current Oncology Reports</i> , 0, , .	1.8	2
233	Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2482-2494.	13.9	83
234	Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. <i>Blood</i> , 2022, 140, 1378-1389.	0.6	14
235	Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. <i>Journal of Clinical Oncology</i> , 2023, 41, 541-554.	0.8	23
236	Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2022, 386, 2495-2506.	13.9	44
237	Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. <i>Blood</i> , 2022, 140, 1907-1916.	0.6	22
238	Late effects in patients with mantle cell lymphoma treated with or without autologous stem cell transplantation. <i>Blood Advances</i> , 2023, 7, 866-874.	2.5	1
239	Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database. <i>Advances in Therapy</i> , 2022, 39, 4792-4807.	1.3	4
240	The Clinical Impact of Precisely Defining Mantle Cell Lymphoma: Contributions of Elaine Jaffe. <i>Hemato</i> , 2022, 3, 508-517.	0.2	0
241	Ixazomib With or Without Rituximab Following Maintenance Autologous Stem Cell Transplant in Mantle Cell Lymphoma: A Single-Center Phase I Trial. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e1084-e1091.	0.2	1
242	Shining a Light on a Randomized Trial: Ibrutinib Plus Rituximab and Bendamustine in Untreated Mantle Cell Lymphoma. , 2022, 19, .		0
243	Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma. <i>Cells</i> , 2022, 11, 2747.	1.8	4
244	Predicting the future in MCL with MRD. <i>Blood</i> , 2022, 140, 1332-1333.	0.6	0
245	Frontline Therapy in Mantle Cell Lymphoma: When Clinical Trial and Real-World Data Collide. <i>Journal of Clinical Oncology</i> , 0, , .	0.8	1
247	Mantle cell lymphoma in <sc>human immunodeficiency virus</sc> â€infectd patients. <i>British Journal of Haematology</i> , 0, , .	1.2	0
248	Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1614-1625.	1.3	4

#	ARTICLE	IF	CITATIONS
249	Burnout, coping and resilience of the cancer care workforce during the SARS-CoV-2: A multinational cross-sectional study. <i>European Journal of Oncology Nursing</i> , 2023, 63, 102204.	0.9	0
250	Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis. <i>EJHaem</i> , 2022, 3, 1165-1171.	0.4	2
252	Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic. <i>Annals of Hematology</i> , 2023, 102, 107-115.	0.8	2
253	Use of Electronic Communication with Clinicians Among Cancer Survivors: Health Information National Trend Survey in 2019 and 2020. <i>Telemedicine Journal and E-Health</i> , 2023, 29, 866-874.	1.6	6
254	CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211421.	1.1	5
255	Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?. <i>European Medical Journal Oncology</i> , 0, , 109-119.	0.0	0
256	Modern approaches in relapsed and refractory Hodgkin lymphoma treatment: literature review and own experience. <i>Journal of Modern Oncology</i> , 2022, 24, 319-324.	0.1	1
257	Bendamustine Plus Rituximab for Mantle Cell Lymphoma: A Korean, Multicenter Retrospective Analysis. <i>Anticancer Research</i> , 2022, 42, 6083-6089.	0.5	2
258	High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2023, 41, 479-484.	0.8	10
259	What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?. <i>Hematology American Society of Hematology Education Program</i> , 2022, 2022, 155-162.	0.9	2
260	Blockade of CCR1 induces a phenotypic shift in macrophages and triggers a favorable antilymphoma activity. <i>Blood Advances</i> , 2023, 7, 3952-3967.	2.5	5
261	Treatment approaches for patients with TP53-mutated mantle cell lymphoma. <i>Lancet Haematology</i> , the, 2023, 10, e142-e154.	2.2	6
262	Long-Term Survival of Patients with Mantle Cell Lymphoma after Total Body Irradiation, High-Dose Chemotherapy and Stem Cell Transplantation: A Monocenter Study. <i>Cancers</i> , 2023, 15, 983.	1.7	1
263	Personalized approaches for treatment-naïve mantle cell lymphoma. <i>Expert Review of Hematology</i> , 2023, 16, 95-107.	1.0	0
264	How I manage mantle cell lymphoma: indolent versus aggressive disease. <i>British Journal of Haematology</i> , 2023, 201, 185-198.	1.2	3
265	Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle cell lymphoma ineligible for intensive therapy: A network meta-analysis. <i>European Journal of Haematology</i> , 0, , .	1.1	0
266	CAR T-Cell therapy for the management of mantle cell lymphoma. <i>Molecular Cancer</i> , 2023, 22, .	7.9	11
267	Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. <i>Blood Advances</i> , 2023, 7, 4518-4527.	2.5	2

#	ARTICLE	IF	CITATIONS
268	Review of management options for mantle cell lymphoma in pregnancy. <i>Leukemia and Lymphoma</i> , 2023, 64, 1194-1198.	0.6	0
269	Candidate germline biomarkers of lenalidomide efficacy in mantle cell lymphoma: the FIL MCL0208 trial. <i>Blood Advances</i> , 0, , .	2.5	0
279	Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. , 2024, , 341-355.		0
280	Hematopoietic Transplantation: Past, Present, and Future. , 2024, , 3-16.		0
285	Stem Cell Transplant for B Cell Non-Hodgkin Lymphoma. , 2023, , 283-334.		0
286	Indications for Autologous Stem Cell Transplant. , 2023, , 239-245.		0
292	Non-Hodgkin lymphoma treated with anti-CD20 antibody-based immunochemotherapy. , 2024, , 103-122.		0
305	Mantelzelllymphom. , 2023, , 179-196.		0
306	Mantle Cell Lymphoma. , 2023, , .		0
311	Circulating Tumor DNA in Lymphoma. <i>Molecular Pathology Library</i> , 2023, , 395-426.	0.1	0
312	Indolente (niedrig maligne) Non-Hodgkin-Lymphome. , 2024, , 491-544.		0